Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Teclison Inc. announced it will participate in the ASCO Gastrointestinal Cancers Symposium, showcasing progress in its GI cancer research efforts.
-
Dewpoint Therapeutics launches Gates Foundation-funded initiative to build and share viral condensate phenomics atlas for HPV.
-
ALISO VIEJO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a late-stage biopharmaceutical company, today announced the appointment of Jean-Frédéric Viret, Ph.D., as the company’s Chief...
-
SIL204 Demonstrated Significant Tumor Inhibition in Positive Pre Clinical Studies with Activity Across Pancreatic, Colorectal, and Lung Cancer Models Company’s Platform Seeks to Address an Estimated...
-
Hummingbird Bioscience today announced that the first patient has been dosed in a Phase I clinical trial of HMBD-501.
-
Paris, Jan. 06, 2026 (GLOBE NEWSWIRE) -- 88% reduction in urinary incontinence episodes in patients with neurogenic bladder sustained through 24 weeksGood tolerability maintainedEnrollment and...
-
Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis on Jan 6, 2026
-
NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...
-
Accomplished industry leader Robert J. Dempsey brings extensive commercialization and ophthalmic expertise Gary S. Jacob, Ph.D., will transition to Chief Development Officer and continue to serve on...
-
IRVING, Texas, Dec. 31, 2025 (GLOBE NEWSWIRE) -- As 2025 ends, BioNTX reflects on a year—and the close of the first quarter of the 21st century—defined by accelerated growth, expanded engagement,...